Dtsch Med Wochenschr 2013; 138(31/32): 1567-1570
DOI: 10.1055/s-0033-1343291
Hämatologie und Onkologie | Commentary
Onkologie
© Georg Thieme Verlag KG Stuttgart · New York

Medikamentöse Behandlung des metastasierten Nierenzellkarzinoms

Drug treatment of metastatic renal cell carcinoma
M. R. Rafiyan
1   Klinik für Onkologie und Hämatologie, Schwerpunkt urologische Onkologie, Palliativmedizin, Krankenhaus Nordwest, Frankfurt
,
E. Jäger
1   Klinik für Onkologie und Hämatologie, Schwerpunkt urologische Onkologie, Palliativmedizin, Krankenhaus Nordwest, Frankfurt
› Author Affiliations
Further Information

Publication History

Publication Date:
08 July 2013 (online)

    Permissions and Reprints

Schlüsselwörter

Nierenzellkarzinom - Sunitinib - Pazopanib - Axitinib

Keywords

renal cell carcinoma - sunitinib - pazopanib - axitinib
 

  • Literatur

  • 1 Algaba F, Akaza H, Lopez-Beltran A et al. Current pathology keys of renal cell carcinoma. Eur Urol 2011; 60: 634-644
    CrossrefSearch in Google Scholar
  • 2 Banumathy G, Cairns P. Signaling pathways in renal cell carcinoma. Cancer Biol Ther 2010; 10: 658-664
    CrossrefSearch in Google Scholar
  • 3 Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Europ J Cancer 2009; 45: 228-247
    CrossrefSearch in Google Scholar
  • 4 Escudier B, Eisen T, Porta C et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (Suppl. 07) vii65-vii71
    CrossrefSearch in Google Scholar
  • 5 Escudier BJ, Bellmunt J, Négrier S et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-alpha2a (IFN) in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2010; 28: 2144-2150
    CrossrefPubMedSearch in Google Scholar
  • 6 Escudier BJ, Porta C, Bono P et al. Patient preference between pazopanib (PAZ) and Sunitinib (Sun): results of a randomized double-blind placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC) – PISCES study, NCT 01064310. J Clin Oncol 2012; 30 (suppl; abstr CRA4502)
    Search in Google Scholar
  • 7 Haas NB, Manola J, Ky B et al. Cardiac safety analysis for a phase III trial of sunitinib (SU) or sorafenib (SO) or placebo (PLC) in patients with resected renal cell carcinoma (RCC). J Clin Oncol 2012; 30 suppl; abstr 4501
    Search in Google Scholar
  • 8 Hall PS, Witteles R, Srinivas S et al. Incidence and severity of cardiotoxicity in metastatic renal cell carcinoma (RCC) patients treated with targeted therapies. J Clin Oncol 2012; 30 suppl; abstr 4610
    Search in Google Scholar
  • 9 Heng DY, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents. J Clin Oncol 2009; 27: 5794-5799
    CrossrefPubMedSearch in Google Scholar
  • 10 Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281
    CrossrefPubMedSearch in Google Scholar
  • 11 Iacovelli R, Cartenì G, Sternberg CN et al. 2. Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort. Eur J Cancer 2013; Mar 18. pii: S0959-8049(13)00164-0. doi: [Epub ahead of print]
    Search in Google Scholar
  • 12 Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol 2003; 170: 2163-2172
    CrossrefSearch in Google Scholar
  • 13 Melchiar B, Bracarda S, Matveev V. Bevacizumab (BEV) + Low-Dose Interferon-α2a (IFN) for firstline treatment of metastatic renal cell carcinoma (MRCC): final safety and efficacy data fom the prospective bevlin study. ESMO 2012; Abstract 1890
    Search in Google Scholar
  • 14 Miller K, Bergmann L, Gschwend J et al. Interdisziplinäre Empfehlungen zur Behandlung des metastasierten Nierenzellkarzinoms. Akt Urol 2011; 42: 242-246
    Thieme ConnectSearch in Google Scholar
  • 15 Motzer R, Hutson TE, Reeves J et al. Randomized, open-label, phase II trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (MRCC): results of the COMPARZ trial. Ann Oncol 2012; 23 (Suppl. 09)
    Search in Google Scholar
  • 16 Motzer RJ, Barrios CH, Kim TM et al. Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2013; 31 suppl; abstr 4504
    Search in Google Scholar
  • 17 Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma. Cancer 2010; 116: 4256-4265
    CrossrefSearch in Google Scholar
  • 18 Motzer RJ, Escudier B, Tomczak P et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma. Lancet Oncol 2013; 14: 552-562
    CrossrefSearch in Google Scholar
  • 19 Motzer RJ, Hutson TE et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24
    CrossrefSearch in Google Scholar
  • 20 Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-3590
    CrossrefSearch in Google Scholar
  • 21 Mc Kay RR, Lin X, Perkins JJ et al. Prognostic significance of bone metastases and biphosphonate therapy in patients with metastatic renal cell carcinoma treated with molecularly targeted agents. J Clin Oncol 2013; 31 (suppl; abstr 4572)
    Search in Google Scholar
  • 22 Robert-Koch-Institut und Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.. Krebs in Deutschland 2007/2008. 8.. Ausgabe. Berlin: Robert Koch-Institut; 2012: 88-91
    Search in Google Scholar
  • 23 Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma. J Clin Oncol 2010; 28: 1061-1068
    CrossrefPubMedSearch in Google Scholar